©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2020; 8(21): 5172-5179
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients
Xiao-Wei Cheng, Wen-Hua Leng, Department of Respiratory and Critical Care Medicine, Panzhihua Central Hospital, Panzhihua 617067, Sichuan Province, China
Chun-Ling Mu, Department of Ultrasound, Panzhihua Central Hospital, Panzhihua 617067, Sichuan Province, China
Author contributions: Cheng XW and Mu CL designed this retrospective study; Leng WH wrote this paper; Cheng XW and Leng WH were responsible for sorting the data.
Institutional review board statement: The study was reviewed and approved by the Panzhihua Central Hospital Institutional Review Board (Approval No. 2019ZD064.1).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available
Corresponding author: Chun-Ling Mu, BM BCh, Attending Doctor, Department of Ultrasound, Panzhihua Central Hospital, No. 34 Yikang Street, East District, Panzhihua 617067, Sichuan Province, China. 470589248@qq.com
Received: June 28, 2020
Peer-review started: June 28, 2020
First decision: July 24, 2020
Revised: August 3, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: November 6, 2020
Processing time: 130 Days and 23.3 Hours
Peer-review started: June 28, 2020
First decision: July 24, 2020
Revised: August 3, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: November 6, 2020
Processing time: 130 Days and 23.3 Hours
Core Tip
Core Tip: A comparative study was conducted to observe the efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients. S-1 maintenance therapy shows a significant therapeutic effect in patients with advanced non-small-cell lung cancer. It has the same clinical efficacy as gemcitabine, but with less toxic and side effects, and is more effective and safer than conventional drugs.